AU Comment: Doravirine and Atazanavir/Ritonavir Australian clinicians should note that neither Atazanavirc o–formulated with ritonavir nor Doravirine are listed on the PBS. Note: All drugs within an ARV class are listed in alphabetical order.
Sub-section: Other Antiretroviral Regimens for Initial Therapy When Abacavir, Tenofovir Alafenamide, and Tenofovir Disoproxil Fumarate Cannot Be Used or Are Not Optimal Most currently recommended antiretroviral (ARV) regimens consist of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third active drug. In some clinical situations, it is preferable to avoid abacavir (ABC), tenofovir alafenamide (TAF), …
Sub-section: Protease Inhibitor-Based Regimens Summary The Food and Drug Administration (FDA)-approved protease inhibitors (PIs) include atazanavir (ATV), ATV/cobicistat (ATV/c), darunavir (DRV), darunavir/cobicistat (DRV/c), fosamprenavir (FPV), indinavir (IDV), lopinavir/ritonavir (LPV/r), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and tipranavir (TPV). PI-based regimens using pharmacokinetic (PK) enhancement with either cobicistat (COBI) or RTV (also called PK boosting) increase …
Summary Five NNRTIs—delavirdine (DLV), doravirine (DOR), efavirenz (EFV), etravirine (ETR), nevirapine (NVP), and rilpivirine (RPV) are currently approved by the Food and Drug Administration (FDA) for the treatment of HIV when used in combination with other antiretroviral (ARV) drugs. This section of the guidelines will focus on DOR, EFV, and RPV, the three NNRTIs recommended …
Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens Read More »
Summary Four integrase strand transfer inhibitors (INSTIs)—bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), and raltegravir (RAL)—are approved for use in antiretroviral therapy (ART)-naive patients with HIV. Cabotegravir (CAB) is a new INSTI that is approved to be used with rilpivirine (RPV) as part of a long-acting injectable complete antiretroviral (ARV) regimen to replace a stable oral …
Integrase Strand Transfer Inhibitor–Based Regimens Read More »
AU comment: Doravirine The non-nucleoside reverse transcriptase inhibitor doravirine (DOR), was approved by the TGA in 2020 as a single drug or as a fixed dose combination with TDF and lamivudine (3TC). DOR/TDF/3TC is NOT reimbursed under the PBS in Australia. Summary The Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) include zidovudine …
AU comment: CAB-LA in Australia Long-acting cabotegravir (CAB-LA) for PrEP was TGA approved in 2022 but is not reimbursed under the PBS or commonly used as PrEP in Australia. However, individuals may have accessed CAB-LA as PrEP while overseas. Clinicians should ensure that integrase genotypic resistance testing is requested to exclude integrase strand transfer inhibitor …
AU Comment: CAB-LA in Australia Long-acting cabotegravir (CAB-LA) for PrEP was TGA approved in 2022 but is not reimbursed under the PBS or commonly used as PrEP in Australia. However, individuals may have accessed CAB-LA as PrEP while overseas. Clinicians should ensure that integrase genotypic resistance testing is requested to exclude integrase strand transfer inhibitor …
Initial Combination ARV Regimens for People with HIV Read More »
This section has information on What to Start. Please click on the below links or follow the table of contents to access the information you are looking for. Initial Combination ARV Regimens for People with HIV Nucleoside Reverse Transcriptase Inhibitor Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens Other ARV Regimens ARV Components or Regimens Not Recommended as …
AU Comment: ART to prevent sexual transmission of HIV in the Australian context This guidance should be read in conjunction with ASHM’s U=U Guidance for Healthcare professionals, which defines an undetectable viral load as: two consecutive undetectable viral load test results separated by at least four weeks; or, more conservatively, a full 6-month period during …
Antiretroviral Therapy to Prevent Sexual Transmission of HIV Read More »
The ARV Guidelines with Australian commentary is administered by ASHM
The Australian Government Department of Health
Prescribers
Contact Us
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2022 ASHM